INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
01/15/2026
Back to search
Official data from USPTO
DIOSYNTH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DIOSYNTH
ST13
US500000079199948Class
1, 5, 40, 42
Filing
79199948
Registration
5273482
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
01/16/2026
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
10/02/2015
Registration date
08/29/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/31/2024
Last transaction
01/16/2026
Responsible office
United States Patent and Trademark Office
Status code
708
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Tokyo, JP
Examiner
GILBERT,REBECCA L
Current location
Historical data usage
Holders and representatives
Holders
F. C. (pessoa física)
Representatives
Mainak H. Mehta Procopio Cory Hargreaves & Savitch
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparations and substances for manufacturing of pharmaceutical productschemical preparations and substances for manufacturing pharmaceutical products for veterinary applications; chemical additives for manufacturing medicines; chemicals for manufacturing cosmeticsskin cleansers and medicines; chemical preservatives for pharmaceutical preparations; biochemicalspolypeptidesrecombinant proteinsorganic peptide substrates and monoclonal antibodies for producing products for genetic pharmacology
Class 5
Medicines and pharmaceutical productsincluding medicines and pharmaceutical products for veterinary usemedicines and pharmaceutical preparations for the treatment of cardiovascular diseasecentral nervous system diseases and disordersneurological disordersurologicalurogenital disorders andgastrointestinal disordersmusculoskeletal disordersallergiesdiabeteshypertensionerectile dysfunctionsexual dysfunctionstrokecancermigrainespainobesityinflammation and inflammatory diseaserespiratory and infectious diseasesimmunologicalbacterialviral and fungal disordersmental illnessdepressionpsychosisbone and mineral diseasesinfertilitymenopausal complaintshormone deficienciessleep disorders; pharmaceutical preparationspreparations to lower cholesterolsmoking cessation preparationstissue and skin repair preparationsdermatological preparationsgynecological preparationscontraceptivesmuscle relaxantsmuscle relaxant antagonists; biotechnological preparations for medical usenamely use in gene therapy; biochemicalsbiochemical preparations for medical usenamely use in gene therapy; genetic materialgenetically engineered tissuefor transplant purposes for genetic cell therapy
Class 40
Custom manufacture of pharmaceuticals
Class 42
Services of biotechnicalchemical and pharmacological laboratoriesscientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations; scientific and technological research relating to the production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparationsscientific consultation related thereto; scientific researchcarrying out early evaluations in the field of new medicines; development of pharmaceutical preparationsmedicines and medicaments; technological servicestechnological consultation and research in the field of new product development in the pharmaceutical and health care industries; scientific analysis and researchevaluation of pharmaceutical products; research and development in the pharmaceutical field; scientific research and development with regard to medicines; product developmentpreparation of pharmaceutical test products; advisory services relating to scientific researchdevelopment and analyses of medicines; development of new technologies in the biotechnology sector; providing information with regard to scientific research in the field of biochemistry and biotechnology; scientific researchincluding in the medical sector
Publications
History of USPTO decisions and trademark events.
37 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
12/08/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
12/08/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
10/09/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
06/30/2025
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
10/31/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
10/31/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
10/12/2024
PR75
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
05/16/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/22/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
08/22/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/13/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/29/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/06/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/13/2017
FIMP
FINAL DISPOSITION PROCESSED
12/13/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/29/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
08/29/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/13/2017
PUBO
PUBLISHED FOR OPPOSITION
06/13/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/24/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/25/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/24/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/24/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/18/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/18/2017
RFNP
REFUSAL PROCESSED BY IB
02/18/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/24/2017
RFRR
REFUSAL PROCESSED BY MPU
01/24/2017
MAFR
APPLICATION FILING RECEIPT MAILED
01/21/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/19/2017
CNRT
NON-FINAL ACTION WRITTEN
01/18/2017
DOCK
ASSIGNED TO EXAMINER
01/17/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/17/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
01/13/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/05/2017
Continuous trademark protection
Get notified about every new filing that threatens DIOSYNTH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.